- Home
- ACIW vs PTGX Comparison
ACIW vs PTGX Comparison
Compare ACIW & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIW
- PTGX
- Stock Information
- Founded
- ACIW 1975
- PTGX 2006
- Country
- ACIW United States
- PTGX United States
- Employees
- ACIW N/A
- PTGX N/A
- Industry
- ACIW EDP Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- ACIW Technology
- PTGX Health Care
- Exchange
- ACIW Nasdaq
- PTGX Nasdaq
- Market Cap
- ACIW 4.7B
- PTGX 4.0B
- IPO Year
- ACIW 1995
- PTGX 2016
- Fundamental
- Price
- ACIW $53.02
- PTGX $65.23
- Analyst Decision
- ACIW Strong Buy
- PTGX Strong Buy
- Analyst Count
- ACIW 3
- PTGX 8
- Target Price
- ACIW $60.00
- PTGX $71.13
- AVG Volume (30 Days)
- ACIW 888.8K
- PTGX 1.0M
- Earning Date
- ACIW 11-06-2025
- PTGX 11-06-2025
- Dividend Yield
- ACIW N/A
- PTGX N/A
- EPS Growth
- ACIW 38.68
- PTGX N/A
- EPS
- ACIW 2.37
- PTGX 0.80
- Revenue
- ACIW $1,700,613,000.00
- PTGX $209,180,000.00
- Revenue This Year
- ACIW $10.58
- PTGX N/A
- Revenue Next Year
- ACIW $6.98
- PTGX $248.17
- P/E Ratio
- ACIW $22.28
- PTGX $81.41
- Revenue Growth
- ACIW 11.22
- PTGX N/A
- 52 Week Low
- ACIW $40.45
- PTGX $33.31
- 52 Week High
- ACIW $59.71
- PTGX $68.26
- Technical
- Relative Strength Index (RSI)
- ACIW 63.47
- PTGX 58.33
- Support Level
- ACIW $51.41
- PTGX $63.71
- Resistance Level
- ACIW $54.28
- PTGX $66.87
- Average True Range (ATR)
- ACIW 1.16
- PTGX 2.53
- MACD
- ACIW -0.01
- PTGX -0.19
- Stochastic Oscillator
- ACIW 70.39
- PTGX 63.47
About ACIW ACI Worldwide Inc.
ACI Worldwide Inc develops, markets and installs a portfolio of software products focused on facilitating electronic payments. The firm also leverages its distribution network in the Americas; Europe, the Middle East, and Africa, or EMEA; and Asia-Pacific regions to sell software developed by third parties. ACI software products process payment transactions for retail banking clients, billers such as utilities and healthcare providers, and community banks and credit unions. ACI's customers are financial institutions all over the world, but majority of the revenue is generated in the United States and EMEA regions.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.